𝔖 Bobbio Scriptorium

✦ LIBER ✦

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Scribed by Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, Leelavathy; Sumathy, T.K.; Shah, Radha; Gopal, M.G.; Narayana Rao, T.; Srinivas, C.R.; Bhat, Ramesh; Shetty, Narendra; Manmohan, G.; Sai Krishna, Kotla; Padmaja, Dalavoi; Pratap, Dasiga Venkata Subrahmanya; Garg, Vijay; Gupta, Sandesh; Pandey, Neeraj; Khopkar, Uday; Montero, Enrique; Ramakrishnan, M.S.; Nair, Pradip; Ganapathi, Prasanna C.

Book ID: 122159631
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 694 KB
Volume: 71
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2014.01.897

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of subcutaneous cert

Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFα monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Adalimumab in Japanese patients with mod

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

✍ Akihiko ASAHINA; Hidemi NAKAGAWA; Takafumi ETOH; Mamitaro OHTSUKI; THE ADALIMUMA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 490 KB

Efficacy and safety of efalizumab in pat

Efficacy and safety of efalizumab in patients with moderate to severe plaque psoriasis*1Pooled results from three phase III randomized, placebo-controlled trials

✍ NAYAK, A 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 27 KB

A multiple dose randomized double-blind

A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris

✍ Gottlieb, AB; Krueger, J; Lebwohl, M; Gisoldi, E; Grossman, RM; Wacholtz, MC 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Efficacy and safety results from a phase

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

✍ B.E. Strober; J.J. Crowley; P.S. Yamauchi; M. Olds; D.A. Williams 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

A phase IV randomized, double-blind, pla

A phase IV randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efalizumab in patients with moderate to severe plaque psoriasis involving the scalp

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB